A few 2025 trials pointed in the same direction: toward treatments built to modify disease biology and better ways to measure ...

A recent study found that Sodium-glucose co-transporter 2 (SGLT2) inhibitors use in hypertrophic cardiomyopathy (HCM) ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

I was with a group of friends recently – drink had been taken, admittedly – and one of them said, “Sometimes I wish I could ...

This move represented a sharp increase in price on volume nearly 3x the average daily trading volume, indicating robust ...

That morning, Edgewise presented interim data from its ongoing Phase 2 clinical trial of EDG-7500, an investigational drug targeting hypertrophic cardiomyopathy (HCM). This is a genetic heart ...

The FDA has approved Myqorzo for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms.